The study also confirmed that 66.7% of tumors in CDH1 carriers exhibited "second-hit" mechanisms of inactivation, such as loss of heterozygosity, additional somatic variant, or promoter methylation, supporting the role of CDH1 in LBC development. The gene discussed is CDH1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.